Hosted on MSN10mon
FDA approves Takeda’s ENTYVIO SC for Crohn’s disease
The US Food and Drug Administration (FDA) has granted approval for Takeda’s ENTYVIO subcutaneous (SC) administration as a maintenance therapy to treat adults with moderately to severely active ...
pharmaphorum1y
Takeda tries again with subcutaneous Entyvio
More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerative colitis. The new ...
Hosted on MSN12mon
Polpharma looks to challenge Takeda’s Entyvio in IBD
Takeda has also invested in sustaining and increasing revenue generated by Entyvio. The company developed a subcutaneous formulation of the monoclonal antibody, which was approved by the US FDA as ...
Healio6d
Stelara, Entyvio have ‘comparable’ cardiovascular safety profiles in older adults with IBD
No significant differences were observed between Stelara and Entyvio in the 3-year risk for a composite of major adverse cardiovascular events. Stelara was linked with lower risk for all-cause ...